Trial Profile
A Phase I Study to Evaluate the Maximum Tolerated Dose (MTD) and Recommended Dose (RD) for Further Development As Well As Long Term Toxicity of Gemcitabine as a Radiosensitizer in Patients with Locally Advanced, Inoperable Bladder Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 20 Nov 2015 New trial record